Tags

Type your tag names separated by a space and hit enter

[Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
Ann Chir Plast Esthet. 2013 Dec; 58(6):658-62.AC

Abstract

AIMS

Raynaud's phenomenon is a vasospastic disorder of the extremities that can lead, in the hands, to pain, disability, ischemic ulcers and digital chronic ischemia. Medical and surgical current treatments are not fully effective while causing side effects. Recent studies have emphasized the value of botulinum toxin type A (BTX A) in the management of primary Raynaud's phenomenon. The originality of Raynaud's syndrome secondary to systemic sclerosis is to combine both arterial vasospasm and sclerosis of the arterial wall, what is supposed to reduce BTX A effects. The purpose of this work is to evaluate BTX A efficiency in patients with Raynaud's phenomenon secondary to systemic sclerosis.

PATIENTS AND METHOD

We performed a prospective study for 12 months. Patients with severe Raynaud's phenomenon due to systemic sclerosis were injected with BTX A in the two hands. Evolution of ischemic ulcers, QuickDASH Score, O2 partial pressure, pain were measured before and 30 days after injection.

RESULTS

We treated 18 patients. Thirty days after injection, we noticed a complete healing of ulcers, QuickDASH Score was improved from 39.4 to 20, as the O2 partial pressure from 16 to 42 mmHg and the pain from VNS from 6/10 to 2/10.

CONCLUSION

BTX A appears to improve significantly Raynaud's phenomenon symptomatology in patients with systemic sclerosis despite the component of arterial sclerosis.

Authors+Show Affiliations

Service de chirurgie de la main, CHU Conception, 145, boulevard Baille, 13005 Marseille, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

fre

PubMed ID

22204894

Citation

Serri, J, et al. "[Botulinum Toxin Type a Contribution in the Treatment of Raynaud's Phenomenon Due to Systemic Sclerosis]." Annales De Chirurgie Plastique Et Esthetique, vol. 58, no. 6, 2013, pp. 658-62.
Serri J, Legré R, Veit V, et al. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis]. Ann Chir Plast Esthet. 2013;58(6):658-62.
Serri, J., Legré, R., Veit, V., Guardia, C., & Gay, A. M. (2013). [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis]. Annales De Chirurgie Plastique Et Esthetique, 58(6), 658-62. https://doi.org/10.1016/j.anplas.2011.11.001
Serri J, et al. [Botulinum Toxin Type a Contribution in the Treatment of Raynaud's Phenomenon Due to Systemic Sclerosis]. Ann Chir Plast Esthet. 2013;58(6):658-62. PubMed PMID: 22204894.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis]. AU - Serri,J, AU - Legré,R, AU - Veit,V, AU - Guardia,C, AU - Gay,A-M, Y1 - 2011/12/26/ PY - 2011/07/06/received PY - 2011/11/13/accepted PY - 2011/12/30/entrez PY - 2011/12/30/pubmed PY - 2014/9/12/medline KW - Botulinum toxin type A KW - Raynaud's phenomenon KW - Sclérodermie systémique KW - Syndrome de Raynaud KW - Systemic sclerosis KW - Toxine botulinique de type A SP - 658 EP - 62 JF - Annales de chirurgie plastique et esthetique JO - Ann Chir Plast Esthet VL - 58 IS - 6 N2 - AIMS: Raynaud's phenomenon is a vasospastic disorder of the extremities that can lead, in the hands, to pain, disability, ischemic ulcers and digital chronic ischemia. Medical and surgical current treatments are not fully effective while causing side effects. Recent studies have emphasized the value of botulinum toxin type A (BTX A) in the management of primary Raynaud's phenomenon. The originality of Raynaud's syndrome secondary to systemic sclerosis is to combine both arterial vasospasm and sclerosis of the arterial wall, what is supposed to reduce BTX A effects. The purpose of this work is to evaluate BTX A efficiency in patients with Raynaud's phenomenon secondary to systemic sclerosis. PATIENTS AND METHOD: We performed a prospective study for 12 months. Patients with severe Raynaud's phenomenon due to systemic sclerosis were injected with BTX A in the two hands. Evolution of ischemic ulcers, QuickDASH Score, O2 partial pressure, pain were measured before and 30 days after injection. RESULTS: We treated 18 patients. Thirty days after injection, we noticed a complete healing of ulcers, QuickDASH Score was improved from 39.4 to 20, as the O2 partial pressure from 16 to 42 mmHg and the pain from VNS from 6/10 to 2/10. CONCLUSION: BTX A appears to improve significantly Raynaud's phenomenon symptomatology in patients with systemic sclerosis despite the component of arterial sclerosis. SN - 1768-319X UR - https://www.unboundmedicine.com/medline/citation/22204894/[Botulinum_toxin_type_A_contribution_in_the_treatment_of_Raynaud's_phenomenon_due_to_systemic_sclerosis]_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0294-1260(11)00183-X DB - PRIME DP - Unbound Medicine ER -